Market overview
The global immunotherapy market is worth USD 77.7 bn in 2026 and is forecast to reach USD 176 bn by 2036, growing at a 8.5% CAGR. United States is the largest country market and Checkpoint inhibitors is the largest by type segment.
| Scope | Immunotherapy medicines: checkpoint inhibitors, cell therapies, T-cell engagers, cancer vaccines, cytokines and allergen immunotherapy, measured at net sales. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 70.0 bn |
| Value 2026 | USD 77.7 bn |
| Value 2036 | USD 176 bn |
| CAGR 2026-2036 | 8.5% |
| Volume 2026 | 2,130 thousand patients |
| Volume 2036 | 5,326 thousand patients |
| Average price 2026 | USD 36,470 per patient |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Immunotherapy market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 77.7 bn |
| 2027 | USD 84.3 bn |
| 2028 | USD 91.5 bn |
| 2029 | USD 99.2 bn |
| 2030 | USD 108 bn |
| 2031 | USD 117 bn |
| 2032 | USD 127 bn |
| 2033 | USD 138 bn |
| 2034 | USD 149 bn |
| 2035 | USD 162 bn |
| 2036 | USD 176 bn |
Immunotherapy market segmentation
By type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Checkpoint inhibitors | 75.0% | 57.0% | USD 58.3 bn | 5.6% |
| Cell therapies | 9.0% | 16.8% | USD 7.0 bn | 15.5% |
| T-cell engagers and bispecifics | 6.0% | 18.6% | USD 4.7 bn | 21.5% |
| Cytokines vaccines and other | 6.0% | 4.6% | USD 4.7 bn | 5.6% |
| Allergen immunotherapy | 4.0% | 3.0% | USD 3.1 bn | 5.6% |
By indication
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Lung cancer | 28.0% | 26.6% | USD 21.8 bn | 7.9% |
| Melanoma | 10.0% | 7.9% | USD 7.8 bn | 5.9% |
| Kidney bladder and urothelial | 12.0% | 11.4% | USD 9.3 bn | 7.9% |
| Other solid tumours | 30.0% | 34.2% | USD 23.3 bn | 9.9% |
| Blood cancers | 12.0% | 13.7% | USD 9.3 bn | 9.9% |
| Allergy and other | 8.0% | 6.3% | USD 6.2 bn | 5.9% |
By administration
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Intravenous | 72.0% | 64.0% | USD 55.9 bn | 7.2% |
| Subcutaneous | 14.0% | 22.0% | USD 10.9 bn | 13.5% |
| Oral and sublingual | 14.0% | 14.0% | USD 10.9 bn | 8.5% |
By line of treatment
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| First-line | 42.0% | 42.0% | USD 32.6 bn | 8.5% |
| Second-line and later | 34.0% | 30.0% | USD 26.4 bn | 7.2% |
| Adjuvant and neoadjuvant | 24.0% | 28.0% | USD 18.6 bn | 10.2% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 56.0% | 52.0% | USD 43.5 bn | 7.7% |
| Cancer centres | 26.0% | 28.0% | USD 20.2 bn | 9.3% |
| Specialty clinics and home care | 18.0% | 20.0% | USD 14.0 bn | 9.7% |
Top 25 countries for immunotherapy by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 84.5% of 2026 revenue and the 25 countries below together hold 95.7%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 38.9 bn | 50.0% | USD 83.4 bn | 7.9% |
| 2 | China | USD 7.0 bn | 9.0% | USD 22.7 bn | 12.5% |
| 3 | Japan | USD 4.7 bn | 6.0% | USD 9.5 bn | 7.4% |
| 4 | Germany | USD 3.9 bn | 5.0% | USD 7.9 bn | 7.4% |
| 5 | France | USD 2.7 bn | 3.5% | USD 5.6 bn | 7.5% |
| 6 | United Kingdom | USD 2.3 bn | 3.0% | USD 4.7 bn | 7.4% |
| 7 | Italy | USD 1.9 bn | 2.5% | USD 4.0 bn | 7.6% |
| 8 | Spain | USD 1.6 bn | 2.0% | USD 3.2 bn | 7.4% |
| 9 | Canada | USD 1.6 bn | 2.0% | USD 3.2 bn | 7.4% |
| 10 | South Korea | USD 1.2 bn | 1.5% | USD 3.2 bn | 10.5% |
| 11 | Australia | USD 925 mn | 1.2% | USD 2.0 bn | 7.8% |
| 12 | Brazil | USD 808 mn | 1.0% | USD 2.1 bn | 10.2% |
| 13 | Netherlands | USD 692 mn | 0.9% | USD 1.5 bn | 7.9% |
| 14 | India | USD 692 mn | 0.9% | USD 2.2 bn | 12.3% |
| 15 | Switzerland | USD 692 mn | 0.9% | USD 1.5 bn | 7.9% |
| 16 | Turkey | USD 575 mn | 0.7% | USD 1.5 bn | 10.3% |
| 17 | Belgium | USD 575 mn | 0.7% | USD 1.2 bn | 7.9% |
| 18 | Mexico | USD 575 mn | 0.7% | USD 1.5 bn | 10.3% |
| 19 | Russia | USD 466 mn | 0.6% | USD 984 mn | 7.8% |
| 20 | Poland | USD 466 mn | 0.6% | USD 1.2 bn | 10.2% |
| 21 | Taiwan | USD 466 mn | 0.6% | USD 984 mn | 7.8% |
| 22 | Austria | USD 466 mn | 0.6% | USD 984 mn | 7.8% |
| 23 | Saudi Arabia | USD 466 mn | 0.6% | USD 1.2 bn | 10.2% |
| 24 | Sweden | USD 466 mn | 0.6% | USD 984 mn | 7.8% |
| 25 | Israel | USD 350 mn | 0.5% | USD 738 mn | 7.8% |
| Rest of world | USD 3.4 bn | 4.3% | USD 7.6 bn | 8.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Merck and Co.
- Bristol Myers Squibb
- Roche
- AstraZeneca
- Regeneron
- Novartis
- Johnson & Johnson
- GSK
Group 2: Regional and specialist players
- Gilead Sciences
- Pfizer
- Amgen
- BeOne Medicines
- Ono Pharmaceutical
- Genmab
- BioNTech
- Summit Therapeutics
Group 3: Emerging and niche players
- Iovance Biotherapeutics
- Legend Biotech
- Innovent Biologics
- Akeso
- Immunocore
- Adaptimmune
- Autolus Therapeutics
- CARsgen Therapeutics
- Arcellx
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the immunotherapy market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.5% is calculated from the resulting values.
The market is divided by type, by indication, by administration, by line of treatment, by end user. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the immunotherapy market?
The global immunotherapy market is estimated at USD 70.0 bn in 2025 and USD 77.7 bn in 2026.
How fast will the immunotherapy market grow?
It is forecast to reach USD 176 bn by 2036, a compound annual growth rate of 8.5% from 2026, an increase of USD 98.0 bn.
Which country is the largest market for immunotherapy?
United States is the largest market by revenue at USD 38.9 bn in 2026, 50.0% of the global total. The three largest countries together hold 65.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 12.5% a year from 2026 to 2036.
Which immunotherapy segment is largest?
In the by type split, Checkpoint inhibitors is the largest segment with 75.0% of 2026 revenue.
Who are the leading immunotherapy companies?
Global leaders include Merck and Co., Bristol Myers Squibb, Roche, AstraZeneca.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- VaccinesUSD 80.6 bn · 7.0% CAGR
- Cardiovascular DevicesUSD 83.8 bn · 7.0% CAGR
- Revenue Cycle ManagementUSD 68.8 bn · 11.0% CAGR
- Drug Delivery SystemsUSD 67.0 bn · 8.0% CAGR
- Contract Research OrganizationUSD 91.8 bn · 8.0% CAGR
- Orthopedic DevicesUSD 65.1 bn · 5.0% CAGR
- Generic InjectableUSD 93.3 bn · 6.3% CAGR
- Ambulatory Surgery CenterUSD 64.2 bn · 7.2% CAGR
← Immunohistochemistry Impedance-based TEER Measurement System →